Deal Tracker · Years
Emerging-market pharma deals in 2025
27 pharma deals announced in 2025 across GCC, MENA, Global (LMICs) & Southeast Asia, tracked by EPT — localization, licensing & distribution. Most active: Local Content and Government Procurement Authority, Bayer, Bio-Thera Solutions & Jamjoom Pharma. Latest: Biocon → Ajanta Pharma (Licensing, 23 Dec 2025).
- EPT has tracked 27 emerging-market pharma deals in 2025.
- The most common structures are localization (33%), licensing (30%) & distribution (15%).
- The countries that appear most often are Saudi Arabia (16), Egypt (4), UAE (4) & China (3).
- Values were disclosed for 3 of 27 deals, totalling $930m; the largest is AriBio → Arcera Life Sciences ($600m, 10 Jun 2025).
- The most active companies: Local Content and Government Procurement Authority (4), Bayer (2), Bio-Thera Solutions (2) & Jamjoom Pharma (2).
- Biocon → Ajanta PharmaLicensing · Global (LMICs) · Undisclosed · 23 Dec 2025
- Accord Healthcare → Dar Al Dawaa Al ArabiyaDistribution · GCC · Undisclosed · 3 Dec 2025
- Algorithm → Batterjee PharmaTechnology transfer / Localization · GCC · Undisclosed · 30 Nov 2025
- Bayer → Alfa PharmaTechnology transfer / Localization · GCC · Undisclosed · 27 Nov 2025
- Local Content and Government Procurement Authority → AJA PharmaTechnology transfer / Localization · GCC · See terms · 22 Nov 2025
- Bayer → Minapharm PharmaceuticalsTechnology transfer / Localization · MENA · Undisclosed · 15 Nov 2025
- Bio-Thera Solutions → Dr. Reddy's LaboratoriesLicensing · Southeast Asia · Undisclosed · 10 Nov 2025
- IMGSA → Omani InvestmentPartnership / Collaboration · GCC · $20m · 3 Nov 2025
- UM6P → InnovX + Moroccan ministries, CGEM and medicines agencyPartnership / Collaboration · MENA · Undisclosed · 3 Nov 2025
- CSL Seqirus → Vaccine IndustrialPartnership / Collaboration · GCC · 30 Oct 2025
- BioRay Pharmaceutical → Tabuk PharmaceuticalsLicensing · MENA · Undisclosed · 29 Oct 2025
- Local Content and Government Procurement Authority → Sudair PharmaTechnology transfer / Localization · GCC · Undisclosed · 28 Oct 2025
- Local Content and Government Procurement Authority → Tabuk PharmaceuticalsTechnology transfer / Localization · GCC · Undisclosed · 28 Oct 2025
- Local Content and Government Procurement Authority → Boston OncologyTechnology transfer / Localization · GCC · Undisclosed · 28 Oct 2025
- Lifera → King Faisal Specialist Hospital & Research CentrePartnership / Collaboration · MENA · Undisclosed · 28 Oct 2025
- Celltrion → Hikma PharmaceuticalsLicensing · MENA · 6 Oct 2025
- Bio-Thera Solutions → Jamjoom PharmaLicensing · MENA · Undisclosed · 15 Sept 2025
- Faes Farma → SIFIM&A / Acquisition · Global (LMICs) · $310m · 2 Sept 2025
- BioGeneric Pharma → GWMTechnology transfer / Localization · GCC · Undisclosed · 30 Jul 2025
- Althera Laboratories → Jamjoom PharmaLicensing · MENA · Undisclosed · 30 Jul 2025
- AriBio → Arcera Life SciencesLicensing · Global (LMICs) · $600m · 10 Jun 2025
- ONConcept® Consortium — Bluepharma · Helm · Welding → Dar Al DawaDistribution · MENA · Undisclosed · 11 May 2025
- Kashiv BioSciences → MS PharmaLicensing · MENA · Undisclosed · 8 May 2025
- Novo Nordisk → LiferaSupply / Manufacturing · GCC · 24 Apr 2025
- Apex Pharma → CIGALAH HealthcareDistribution · GCC · Undisclosed · 17 Apr 2025
- EQL Pharma → PharmalinkDistribution · GCC · See terms · 11 Mar 2025
- Sandoz → SEDICOTechnology transfer / Localization · MENA · Undisclosed · 6 Mar 2025
Most active companies
Local Content and Government Procurement Authority (4) · Bayer (2) · Bio-Thera Solutions (2) · Jamjoom Pharma (2) · Lifera (2) · Tabuk Pharmaceuticals (2)
Largest disclosed deals
- AriBio → Arcera Life Sciences · $600m · Licensing · 10 Jun 2025
- Faes Farma → SIFI · $310m · M&A / Acquisition · 2 Sept 2025
- IMGSA → Omani Investment · $20m · Partnership / Collaboration · 3 Nov 2025
Questions
- How many emerging-market pharma deals in 2025 has EPT tracked?
- 27 as of 23 Dec 2025. The most recent is Biocon → Ajanta Pharma (Licensing, 23 Dec 2025).
- What types of emerging-market pharma deals in 2025 are most common?
- Technology transfer / Localization: 9 (33%); Licensing: 8 (30%); Distribution: 4 (15%); Partnership / Collaboration: 4 (15%).
- Which companies are most active in emerging-market pharma deals in 2025?
- Local Content and Government Procurement Authority (4 deals), Bayer (2 deals), Bio-Thera Solutions (2 deals), Jamjoom Pharma (2 deals), Lifera (2 deals), Tabuk Pharmaceuticals (2 deals).
- What is the largest disclosed emerging-market pharma deal in 2025?
- AriBio → Arcera Life Sciences: $600m (Licensing, 10 Jun 2025); Faes Farma → SIFI: $310m (M&A / Acquisition, 2 Sept 2025); IMGSA → Omani Investment: $20m (Partnership / Collaboration, 3 Nov 2025). Values are as announced by the parties.
- Which countries appear most in emerging-market pharma deals in 2025?
- Saudi Arabia (16), Egypt (4), UAE (4), China (3), Germany (3), India (2) — counting where the parties are based and the markets the deals cover.
Browse deals
By region
GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)
By country
Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)
By deal type
Licensing (56) · Distribution (41) · Technology transfer / Localization (39) · Partnership / Collaboration (35) · M&A / Acquisition (21) · Equity / Investment (18) · Joint venture (11) · Supply / Manufacturing (10)
Popular searches
MENA pharma licensing deals (25) · Saudi Arabia pharma licensing deals (24) · GCC pharma distribution deals (21) · GCC pharma partnerships (19) · China pharma licensing deals (17) · UAE pharma distribution deals (17) · GCC pharma localization & tech-transfer deals (15) · Saudi Arabia pharma distribution deals (14) · UAE pharma partnerships (13) · UAE pharma licensing deals (12) · Global (LMICs) pharma licensing deals (11) · India pharma licensing deals (11) · GCC pharma licensing deals (10) · MENA pharma partnerships (10) · Saudi Arabia pharma localization & tech-transfer deals (10) · MENA pharma localization & tech-transfer deals (9) · United States pharma licensing deals (9) · Egypt pharma localization & tech-transfer deals (8) · Saudi Arabia pharma partnerships (8) · CIS & Central Asia pharma localization & tech-transfer deals (7) · Kazakhstan pharma localization & tech-transfer deals (7) · MENA pharma distribution deals (7) · MENA pharma M&A deals (7) · United States pharma distribution deals (7)
By company
ADCAN Pharma (13) · Mubadala Bio (8) · Jamjoom Pharma (7) · SPIMACO (7) · Arcera Life Sciences (6) · Hikma Pharmaceuticals (6) · Bio-Thera Solutions (6) · Avalon Pharma (5) · Tabuk Pharmaceuticals (5) · Local Content and Government Procurement Authority (5) · Kazakhstan Ministry of Health (5) · Eva Pharma (4) · Sandoz (4) · Department of Health – Abu Dhabi (4) · Biocon (4) · Groupe Saidal (4) · Gilead Sciences (3) · Dr. Reddy's Laboratories (3) · Emirates Drug Establishment (3) · Novo Nordisk (3) · Khazaen Economic City (3) · Galenicum (3) · Roche (3) · Laprophan (3) · Sanofi (3) · Gen İlaç (3) · Taiba Healthcare (3) · Dar Al Dawa (3) · Lifera (3) · Celltrion (2) · Viatris (2) · Rem3dy Health (2) · AMA Medical Manufacturing (2) · Afreximbank (2) · M42 (2) · Abbott (2) · DKSH (2) · Adalvo (2) · Rameda (2) · Menarini (2) · Korea United Pharm (2) · Samsung Bioepis (2) · AstraZeneca (2) · MS Pharma (2) · LifePharma (2) · Duopharma Biotech (2) · JCR Pharmaceuticals (2) · Philex Pharmaceuticals (2) · Lotus Pharmaceutical (2) · Elpen (2) · Dhofar Pharmaceutical Industries (2) · Accord Healthcare (2) · CCL Pharmaceuticals (2) · Abdi İbrahim (2) · Nordic Pharma (2) · UNIMED Laboratories (2) · Minapharm (2) · SaudiVax (2) · Faes Farma (2) · AJA Pharma (2) · VACSERA (2) · Bayer (2) · Shanghai Henlius Biotech (2) · Julphar (2)
By therapeutic area
Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)